QLT Photofrin Expanded Lung Cancer Use Covers Up To 25,000 Patients
This article was originally published in The Gray Sheet
Executive Summary
QLT estimates that 20,000 to 25,000 patients will be eligible for Photofrin photodynamic therapy under an expanded lung cancer indication recommended by FDA's Oncologic Drugs Advisory Committee Sept. 3.